Увійти

Готові списки джерел за темами / Chronic liver disease and Non invasive marker / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Chronic liver disease and Non invasive marker.

Статті в журналах з теми "Chronic liver disease and Non invasive marker"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Chronic liver disease and Non invasive marker".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Dr., Muhammad Adnan Bawany *. Dr. Tariq Zaffar Shaikh Dr Abdul Rahim Memon Dr. Syed Zulfiquar Ali Shah Dr. Jesse Suarez Dr. Samreen. "NON INVASIVE MARKER (AST/ALT RATIO) TO PREDICT FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASE." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4358–61. https://doi.org/10.5281/zenodo.1064339.

Повний текст джерела

Анотація:

Objective: To evaluate the AST/ALT ratio to predict fibrosis in patients with chronic liver disease at tertiary care hospital Patients and Methods: Total fifty patients, of 12 to 50 years either gender had chronic liver disease by positive HCV RNA PCR and/or HBs Ag, and had liver biopsy done for evaluation purposes were enrolled and entered in this six months cross sectional study after informed consent. The brief history was taken and relevant clinical examination was performed while the laboratory investigations includes liver function test, serum albumin, ultrasound abdomen, prothrombin tim

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Dr., Abdul Rahim Memon *. Dr. Nand Lal Seerani Dr. Majid Ali Soomro Dr. Imran Karim Dr. Ramon A. Docobo and Dr. Samreen. "FORNS INDEX TO PREDICT FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASE." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4362–65. https://doi.org/10.5281/zenodo.1064341.

Повний текст джерела

Анотація:

Objective: To estimate the Forns index to predict fibrosis in patients with chronic liver disease at tertiary care hospital Patients and Methods: Total Fifty patients, of 12 to 50 years either gender had chronic liver disease by positive HCV RNA PCR and/or HBsAg, and had liver biopsy done for evaluation purposes were enrolled and entered in this six months cross sectional study after informed consent. The brief history was taken and relevant clinical examination was performed while the laboratory investigations include latelet count, γ-glutamyl transferase (GGT), and cholesterol levels.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Orasan, Olga Hilda, George Ciulei, Angela Cozma, Madalina Sava, and Dan Lucian Dumitrascu. "Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies." Medicine and Pharmacy Reports 89, no. 1 (2016): 24–31. http://dx.doi.org/10.15386/cjmed-554.

Повний текст джерела

Анотація:

Chronic liver diseases represent a significant public health problem worldwide. The degree of liver fibrosis secondary to these diseases is important, because it is the main predictor of their evolution and prognosis.Hyaluronic acid is studied as a non-invasive marker of liver fibrosis in chronic liver diseases, in an attempt to avoid the complications of liver puncture biopsy, considered the gold standard in the evaluation of fibrosis. We review the advantages and limitations of hyaluronc acid, a biomarker, used to manage patients with chronic viral hepatitis B or C infection, non-alcoholic f

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Loomba, Rohit, and Leon A. Adams. "Advances in non-invasive assessment of hepatic fibrosis." Gut 69, no. 7 (2020): 1343–52. http://dx.doi.org/10.1136/gutjnl-2018-317593.

Повний текст джерела

Анотація:

Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts the risk of future liver-related morbidity and thus need for treatment, monitoring and surveillance. Non-invasive fibrosis tests (NITs) overcome many limitations of liver biopsy and are now routinely incorporated into specialist clinical practice. Simple serum-based tests (eg, Fibrosis Score 4, non-alcoholic fatty liver disease Fibrosis Score) consist of readily available biochemical surrogates and clinical risk factors for liver fibrosis (eg, age and sex). These have been extensively validated acros

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Mihaylov, R., B. Pencheva, D. Stoeva, and A. Ruseva. "Non-invasive Diagnostics of Liver Fibrosis." Acta Medica Bulgarica 44, no. 1 (2017): 50–56. http://dx.doi.org/10.1515/amb-2017-0009.

Повний текст джерела

Анотація:

Abstract Detecting new units of pathogenesis in the liver fibrosis due to alcoholism, chronic viral Hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), autoimmune, parasitic and metabolic diseases and other, reveals perspective for new non-invasive serum biomarkers. In fibrosis, from the wide variety of markers enzymes, proteins and cytokines are mainly used. While direct biomarkers reflect the stage of fibrosis and fibrinogenesis, indirect markers allow assessment of the general liver functions. The combination of direct and indirect markers increases the diagnostic reliability and

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Nachit, Maxime. "Precision imaging in chronic liver disease management." Acta Gastro Enterologica Belgica 88, no. 1 (2025): 61. https://doi.org/10.51821/88.1.14128.

Повний текст джерела

Анотація:

Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over a quarter of the global population, with up to 30% developing Metabolic Dysfunction-Associated Steatohepatitis (MASH), a progressive form that can silently lead to fibrosis, cirrhosis, and liver cancer. Current diagnostic methods, including blood-based scores and imaging, are insufficient for early detection, leading to late-stage diagnoses in most patients. Liver biopsy remains the diagnostic gold standard but is invasive, costly, and prone to high inter- and intra-reader variability, limiting its utility in routine car

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Egresi, Anna, Anna Blázovics, Gabriella Lengyel, et al. "Redox Homeostasis and Non-Invasive Assessment of Significant Liver Fibrosis by Shear Wave Elastography." Diagnostics 14, no. 17 (2024): 1945. http://dx.doi.org/10.3390/diagnostics14171945.

Повний текст джерела

Анотація:

Hepatic fibrosis with various origins can be estimated non-invasively by using certain biomarkers and imaging-based measurements. The aim of our study was to examine redox homeostasis biomarkers and liver stiffness measurements for the assessment of significant liver fibrosis in different etiologies of chronic liver diseases. A cohort study consisting of 88 chronic liver disease patients of both sexes (age 49.1 ± 14.7 years) was performed. Cytokine profiles as well as redox homeostasis characteristics were determined. Liver fibrosis stages were assessed with shear wave elastography. The plasma

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Patel, Preya Janubhai, Declan Connoley, Freya Rhodes, Ankur Srivastava, and William Rosenberg. "A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 57, no. 1 (2019): 36–43. http://dx.doi.org/10.1177/0004563219879962.

Повний текст джерела

Анотація:

The rising incidence of chronic liver disease continues to be an increasing health burden. The morbidity and mortality associated with chronic liver disease typically occur in patients with advanced fibrosis. Hence, early identification of those at-risk is of vital importance to ensure appropriate ongoing management. Currently, tools for appropriate risk stratification remain limited. Increasing awareness of the limitations of liver biopsy has driven research into alternative non-invasive methods of fibrosis assessment including serological markers assessing functional changes. One such biomar

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Aslam, Hunain, Fouzia Oza, Khalid Ahmed, et al. "The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review." International Journal of Molecular Sciences 24, no. 4 (2023): 3487. http://dx.doi.org/10.3390/ijms24043487.

Повний текст джерела

Анотація:

Liver disease is one of the leading public health problems faced by healthcare practitioners regularly. As such, there has been a search for an inexpensive, readily available, non-invasive marker to aid in monitoring and prognosticating hepatic disorders. Recently, red blood cell distribution width (RDW) has been found to be associated with various inflammatory conditions with implications for its use as a potential marker for assessing disease progression and prognosis in multiple conditions. Multiple factors effect red blood cell production whereby a dysfunction in any process can lead to an

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Cho, Eun Hye, Jee Ah Kim, Min-Seung Park, Min-Jung Kwon, Hyosoon Park, and Hee-Yeon Woo. "Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease." PLOS ONE 20, no. 2 (2025): e0318847. https://doi.org/10.1371/journal.pone.0318847.

Повний текст джерела

Анотація:

Introduction Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Accurate assessment of liver fibrosis is essential for the prognosis and management of NAFLD. Mean platelet volume (MPV), an index of platelet activation, has been associated with liver fibrosis in various chronic liver diseases; however, its role in NAFLD remains uncertain. Methods This study analyzed data from 70,830 patients with NAFLD who underwent a comprehensive health examination between 2015 and 2019. Patients were stratified into three groups based on the fibrosis-4 (

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Egresi, Anna, Gabriella Lengyel, and Krisztina Hagymási. "Non-invasive assessment of fatty liver." Orvosi Hetilap 156, no. 14 (2015): 543–51. http://dx.doi.org/10.1556/oh.2015.30123.

Повний текст джерела

Анотація:

As the result of various harmful effects (infectious agents, metabolic diseases, unhealthy diet, obesity, toxic agents, autoimmune processes) hepatic damage may develop, which can progress towards liver steatosis, and fibrosis as well. The most common etiological factors of liver damages are hepatitis B and C infection, alcohol consumption and non-alcoholic fatty liver disease. Liver biopsy is considered as the gold standard for the diagnosis of chronic liver diseases. Due to the dangers and complications of liver biopsy, studies are focused on non-invasive markers and radiological imaging for

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Popa, Alexandru, Ioan Sporea, Felix Bende, et al. "The Non-Invasive Ultrasound-Based Assessment of Liver Viscosity in a Healthy Cohort." Diagnostics 12, no. 6 (2022): 1451. http://dx.doi.org/10.3390/diagnostics12061451.

Повний текст джерела

Анотація:

Liver fibrosis is the most significant prognostic factor in chronic liver disease (CLD). Clinical practice guidelines recommend the use of non-invasive techniques, such as two-dimensional shear-wave elastography (2D-SWE), to assess liver stiffness as a marker of fibrosis. Several other factors influence liver stiffness in addition to liver fibrosis. It is presumed that changes due to necro-inflammation modify the propagation of shear waves (dispersion). Therefore, new imaging techniques that investigate the dispersion properties of shear waves have been developed, which can serve as an indirec

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Bajraktari, Ganimete, Tanja Elger, Muriel Huss, et al. "Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis." International Journal of Molecular Sciences 25, no. 9 (2024): 4765. http://dx.doi.org/10.3390/ijms25094765.

Повний текст джерела

Анотація:

Primary sclerosing cholangitis (PSC) is a serious liver disease associated with inflammatory bowel disease (IBD). Galectin-3, an inflammatory and fibrotic molecule, has elevated circulating levels in patients with chronic liver disease and inflammatory bowel disease (IBD). This study aims to clarify whether galectin-3 can differentiate between patients with IBD, PSC, and PSC-IBD. Our study measured serum galectin-3 levels in 38 healthy controls, 55 patients with IBD, and 22 patients with PSC (11 patients had underlying IBD and 11 patients did not), alongside the urinary galectin-3 of these pat

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Egresi, Anna, Gabriella Lengyel, and Krisztina Hagymási. "Options of non-invasive assessment of liver fibrosis based on the clinical data." Orvosi Hetilap 156, no. 2 (2015): 43–52. http://dx.doi.org/10.1556/oh.2015.30069.

Повний текст джерела

Анотація:

Liver cirrhosis is one of the leading causes of death worldwide. Liver biopsy is considered as the gold standard for the diagnosis of chronic liver diseases. Studies have focused on non-invasive markers for liver fibrosis because of the dangers and complications of liver biopsy. The authors review the non-invasive direct as well as indirect methods for liver fibrosis assessment and present the positive and negative predictive value, sensitivity and specificity of those. Clinical utilities of transient elastography (Fibrsocan) is also reviewed. Non-invasive methods are useful in the assessment

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Olteanu, Vasile-Andrei, Gheorghe G. Balan, Oana Timofte, et al. "Risk Predictors of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease." Diagnostics 12, no. 9 (2022): 2136. http://dx.doi.org/10.3390/diagnostics12092136.

Повний текст джерела

Анотація:

The assessment of fibrosis in chronic liver diseases using non-invasive methods is an important topic in hepatology. The aim of this study is to identify patients with non-alcoholic fatty liver disease (NAFLD) and advanced liver fibrosis by establishing correlations between biological/ultrasound markers and non-invasively measured liver stiffness. This study enrolled 116 patients with non-alcoholic fatty liver disease, which were evaluated clinically, biologically, and by ultrasound. Liver fibrosis was quantified by measuring liver stiffness by shear wave elastography (SWE). Multiple correlati

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Diaconu, Catalina, Florentina Ionita Radu, Mariana Jinga, et al. "From liver biopsy to non-invasive markers in evaluating fibrosis in chronic liver disease." Romanian Journal of Military Medicine 118, no. 2 (2015): 5–12. http://dx.doi.org/10.55453/rjmm.2015.118.2.1.

Повний текст джерела

Анотація:

Chronic liver disease is a late stage of progressive hepatic fibrosis. It consists of functional and structural disruptions in most chronic liver diseases. An accurate diagnosis allows us to establish the degree of fibrosis and the stage of the disease, the prognosis of the patient and to predict a treatment response. Despite the fact that liver biopsy is considered a gold standard, noninvasive methods for diagnosing liver fibrosis have gained more and more importance. Whether we talk about serum biomarkers or imagistic methods from transient elastography to 3-D magnetic resonance elastography

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Liu, Tianhui, Xiaoming Wang, Morten A. Karsdal, Diana J. Leeming, and Federica Genovese. "Molecular Serum Markers of Liver Fibrosis." Biomarker Insights 7 (January 2012): BMI.S10009. http://dx.doi.org/10.4137/bmi.s10009.

Повний текст джерела

Анотація:

Fibrosis is a hallmark histologic event of chronic liver diseases and is characterized by the excessive accumulation and reorganization of the extracellular matrix (ECM). The gold standard for assessment of fibrosis is liver biopsy. As this procedure has various limitations, including risk of patient injury and sampling error, a non-invasive serum marker for liver fibrosis is desirable. The increasing understanding of the pathogenesis of hepatic fibrosis has suggested several markers which could be useful indicators of hepatic fibrogenesis and fibrosis. These markers include serum markers of l

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Frączek, Julia, Aleksandra Sowa, Paulina Agopsowicz, Maciej Migacz, Katarzyna Dylińska-Kala, and Michał Holecki. "Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD." Medicina 61, no. 4 (2025): 736. https://doi.org/10.3390/medicina61040736.

Повний текст джерела

Анотація:

Metabolic dysfunction-associated steatotic fatty liver disease (MASLD) is a worsening global health issue, affecting over one-third of the adult population and representing the leading cause of liver-related morbidity and mortality. MASLD is not only a key precursor to chronic liver disease, but also a systemic condition that leads to numerous extrahepatic complications, increasing the risk of cardiovascular diseases, chronic kidney disease, type 2 diabetes, and certain cancers. The primary reference method for assessing liver fibrosis, allowing for precise determination of its location and se

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Buivydienė, Arida, Viktorija Basytė, and Jonas Valantinas. "Non-invasive serum markers and transient elastography in staging advanced chronic hepatitis C." Acta medica Lituanica 22, no. 4 (2016): 188–95. http://dx.doi.org/10.6001/actamedica.v22i4.3237.

Повний текст джерела

Анотація:

Objectives. In the past decade researchers are presenting indirect non-invasive serum markers for liver fibrosis and cirrhosis evaluation. Our aim was to evaluate effectiveness in staging advanced liver disease when using transient elastography and nine non-invasive serum markers: APRI, FIB-4, ASPRI, LSPS, P2/MS, FibroQ, Fibro-α, Pohl, CDR. Methods. 162 patients with hepatitis C infection were included in this study. Patients were divided in two groups, regarding histopathologic results: advanced liver fibrosis and cirrhosis. The following laboratory measures were obtained in all patients: ALT

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Ismaiel, Abdulrahman, Evrard Katell, Daniel-Corneliu Leucuta, et al. "The Impact of Non-Invasive Scores and Hemogram-Derived Ratios in Differentiating Chronic Liver Disease from Cirrhosis." Journal of Clinical Medicine 14, no. 9 (2025): 3072. https://doi.org/10.3390/jcm14093072.

Повний текст джерела

Анотація:

Background: Chronic liver disease (CLD) is a major global health concern, contributing significantly to morbidity and mortality. Cirrhosis and liver cancer are the leading causes of liver-related deaths, with various etiological factors, such as metabolic disorders and alcohol-related and viral hepatitis, driving its global prevalence. Non-invasive biomarkers and scoring systems have emerged as key tools for assessing liver disease severity and differentiating CLD from cirrhosis. This study evaluates biomarkers and non-invasive scores and their utility in distinguishing CLD from cirrhosis. Met

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Leszczynska, Aleksandra, Christian Stoess, Hana Sung, Davide Povero, Akiko Eguchi, and Ariel Feldstein. "Extracellular Vesicles as Therapeutic and Diagnostic Tools for Chronic Liver Diseases." Biomedicines 11, no. 10 (2023): 2808. http://dx.doi.org/10.3390/biomedicines11102808.

Повний текст джерела

Анотація:

Chronic liver diseases can lead to fibrotic changes that may progress to the development of cirrhosis, which poses a significant risk for morbidity and increased mortality rates. Metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and viral hepatitis are prevalent liver diseases that may lead to cirrhosis. The advanced stages of cirrhosis can be further complicated by cancer development or end-stage liver disease and liver failure. Hence, early detection and diagnosis of liver fibrosis is crucial for preventing the progression to cirrhosis

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Biagi, Filippo, Francesco Carlomagno, Martina Carbone, et al. "Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication." Metabolites 13, no. 11 (2023): 1119. http://dx.doi.org/10.3390/metabo13111119.

Повний текст джерела

Анотація:

Fibroblast growth factor 21 (FGF-21), previously recognized as a marker of liver damage and a potential drug target in non-alcoholic fatty liver disease (NAFLD), has unclear implications in hepatitis C virus (HCV) infections. This study aimed to investigate the relationship between FGF-21 levels and liver health in patients with HCV undergoing direct-acting antiviral (DAA) treatment. Forty-five patients were assessed for liver stiffness, blood chemistry, and other relevant metrics before and after achieving sustained viral response (SVR), defined as the absence of detectable HCV-RNA after 24 w

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Aida, Yuta, Hiroshi Abe, Yoichi Tomita, et al. "Serum Immunoreactive Collagen IV detected by Monoclonal Antibodies as a Marker of Severe Fibrosis in Patients with Non- Alcoholic Fatty Liver Disease." Journal of Gastrointestinal and Liver Diseases 24, no. 1 (2015): 61–68. http://dx.doi.org/10.15403/jgld.2014.1121.yad.

Повний текст джерела

Анотація:

Background & Aims: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. We evaluated serum collagen IV as a direct non-invasive marker of severe liver fibrosis in NAFLD.Methods: The study included 148 NAFLD and 187 chronic hepatitis C patients in whom histological severity of liver fibrosis was evaluated. The utility of serum collagen IV measured by immune-mediated agglutination using two types of monoclonal antibodies for distinguishing severe fibrosis (≥ stage 3 and ≥ F3) from non-to-moderate fibrosis in NAFLD or chronic hepatitis C was assessed in comparis

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Devi, S., Suchanda Sahu, VL Vennala, MK Panigrahi, and KK Behera. "Comparison of Clinico-Biochemical and Transient Elastography Findings Among Diabetic and Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease." Series of Endocrinology, Diabetes and Metabolism 6, no. 2 (2024): 1–9. http://dx.doi.org/10.54178/jsedmv6i2001.

Повний текст джерела

Анотація:

Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease. It is characterized by a wide range of symptoms like fatigue, pain, or dullness in the upper right quadrant of the abdomen or none at all. The risk factors linked to NAFLD are type 2 diabetes mellitus (T2DM), obesity, and genetic predisposition. In this study, the clinical, biochemical, and ultrasonography findings were compared in NAFLD patients with and without T2DM. The liver elastography (FibroScan) measured liver stiffness (LSM), and the liver fibrosis index 4 (FIB-4) were both significantly higher in diabet

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Stepanov, Yu.M., V.I. Didenko, I.A. Klenina, O.M. Tatarchuk, and O.P. Petishko. "Improvement of liver fibrosis verification using new minimally invasive markers in patients with chronic diffuse liver diseases." Medicni perspektivi 27, no. 4 (2022): 100–114. https://doi.org/10.26641/2307-0404.2022.4.271181.

Повний текст джерела

Анотація:

The aim of our research was to obtain new minimally invasive serum markers of fibrotic changes of liver in patients with chronic diffuse liver diseases of different etiology and compare them with traditional markers. 364 patients aged 30 to 66 years were examined: 221 women (60.7%) and 143 men (39.3%). Depending on the etiological factors, all patients were divided into 4 groups: group I consisted of 108 patients with non-alcoholic fatty liver disease (NAFLD), group II – 143 patients with chronic hepatitis associated with virus C (CHC), group III – 56 patients with alcoholic liver

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Mukewar, Shrikant. "Recent advances in diagnosis and management of chronic cholestatic liver diseases: expert consensus." International Journal of Research in Medical Sciences 13, no. 2 (2025): 967–76. https://doi.org/10.18203/2320-6012.ijrms20250288.

Повний текст джерела

Анотація:

Chronic cholestatic liver diseases (CCLD), primarily including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are characterized by impaired bile flow, leading to systemic complications such as pruritus, jaundice, fat soluble vitamin deficiencies and progressive liver damage. Recent advances in diagnostics, particularly the use of non-invasive tests like FIB-4, APRI and transient elastography, have significantly improved the early detection and assessment of liver fibrosis. Ursodeoxycholic acid (UDCA) remains the cornerstone treatment for PBC, effectively improving

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Malhotra, Parveen, Vani Malhotra, Naveen Malhotra, Ajay Chugh, Abhisekh, and Yogesh Sanwariya. "Nonalcoholic fatty liver disease - Non-invasive markers of fibrosis or liver biopsy for determining liver fibrosis." Journal of Nutrition Research 6, no. 1 (2018): 100–106. http://dx.doi.org/10.55289/jnutres/v6i1.1.

Повний текст джерела

Анотація:

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease & liver transplantation and its incidence is increasing even in Asian countries. The gold standard for assessing hepatic fibrosis is liver histology but due to its limitations, noninvasive tests to assess hepatic fibrosis which can be used as alternative to liver biopsy have been developed. In a cross-sectional study, 25 diagnosed NAFLD patients underwent detailed laboratory investigations including the specific non-invasive markers of fibrosis namely, Haptoglobin, Alpha-2 macroglobulin, Apolipoprotein- A1

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Elabd, Elham Youssef, Diaa El-Din Mohammad Soliman El-Beik, Essam Mohammed Bayoumy, et al. "Diagnostic Value of Acyl-Ghrelin in Type 2 Diabetic Patients with Non-alcoholic Fatty Liver Disease." Open Access Macedonian Journal of Medical Sciences 10, B (2022): 470–76. http://dx.doi.org/10.3889/oamjms.2021.7548.

Повний текст джерела

Анотація:

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide. Type 2 diabetes (T2D) is described as one of the most significant risk factor for developing NAFLD, non-alcoholic steatohepatitis, and advanced cirrhosis. Liver biopsy cannot be used routinely to diagnose NAFLD. Therefore, it is critically urgent to develop a simple non-invasive test. AIM: This study examined fasting Acyl-Ghrelin (AG) as a non-invasive biomarker to accurately diagnose NAFLD in diabetic patients. PATIENTS AND METHODS: Sixty-one patients with T2D were divided int

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Bolakhe, Kalasha, Pabitra Bista, Tika Bahadur Thapa, et al. "Study of Hepatic Steatosis Algorithms as A Potential Marker of Metabolic Dysfunction Associated Steatotic Liver Disease." Journal of Manmohan Memorial Institute of Health Sciences 9, no. 2 (2024): 8–12. http://dx.doi.org/10.3126/jmmihs.v9i2.71793.

Повний текст джерела

Анотація:

Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, with increased liver-related morbidity and mortality. Various non-invasive algorithms have been developed for predicting the presence of MASLD using anthropometric and biochemical parameters. Hence, this study aims to determine hepatic steatosis algorithms as a potential marker of MASLD. Methods: A total of 200 participants were included in the study, of which 100 were MASLD cases, and 100 were healthy control. Serum ALT, AST, TG, and Glucose were estimated, and Hepa

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Martinou, Eirini, Marinos Pericleous, Irena Stefanova, Vasha Kaur, and Angeliki M. Angelidi. "Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches." Diagnostics 12, no. 2 (2022): 407. http://dx.doi.org/10.3390/diagnostics12020407.

Повний текст джерела

Анотація:

Non-Alcoholic Fatty Liver Disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted disorder, and its spectrum includes steatosis to steatohepatitis, which may evolve to advanced fibrosis and cirrhosis. In addition, the presence of NAFLD is independently associated with a higher cardiometabolic risk and increased mortality rates. Considering that the vast majority of individuals with NAFLD are mainly asymptomatic, early diagnosis of non-alcoholic steatohepatitis (NASH) and accurate staging of fibros

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Khalil, Mohammed, Abeer Sharaf Eldin, Ahmed Ahmed, Bahaa Badr, and Ayman Yassin. "Serum total IgE as immunological marker in patients with chronic hepatitis B Virus infection, and hepatitis B related hepatocellular carcinoma." Egyptian journal of Immunology 30, no. 1 (2023): 96–104. http://dx.doi.org/10.55133/eji.300110.

Повний текст джерела

Анотація:

This study evaluated the efficacy of IgE in predicting disease progression in chronic hepatitis B virus (HBV) and HBV related hepatocellular carcinoma (HCC) compared to normal controls. The study included 60 HBV-infected patients. Of these, 30 patients with chronic hepatitis B but not related to HCC and 30 patients with related HCC. Serum level of IgE was measured by ELISA. Serum level of IgE was higher in HCC patients than non-HCC patients (p< 0.005). Significant correlations were detected between IgE, transaminases (ALT, AST), alpha-fetoprotein and severity scores in chronic hepatitis B (

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Pár, Alajos, Áron Vincze, and Gabriella Pár. "Nem invazív fibrosisdiagnosztika hepatitis C-vírus-infekcióban: szerepe a kezelés indikációjában, követésében és a prognózis megítélésében." Orvosi Hetilap 156, no. 21 (2015): 855–61. http://dx.doi.org/10.1556/650.2015.30173.

Повний текст джерела

Анотація:

Chronic hepatitis C virus infection associated with necroinflammation predisposes to liver fibrosis and cirrhosis, which lead to severe end-stage complications. Staging of fibrosis is of basic importance for the indication of antiviral treatment, for monitoring the response and predicting the prognosis of patients with hepatitis C virus related liver disease. Since liver biopsy, the “gold standard” diagnosis of fibrosis is invasive and it has some other limitations, non-invasive methods have been developed and widely used in the clinical practice. Serum biomarkers and physical approaches measu

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Alempijevic, Tamara, Simon Zec, Vladimir Nikolic, et al. "Doppler ultrasonography combined with transient elastography improves the non-invasive assessment of fibrosis in patients with chronic liver diseases." Medical Ultrasonography 19, no. 1 (2017): 7. http://dx.doi.org/10.11152/mu-921.

Повний текст джерела

Анотація:

Aims: Accurate clinical assessment of liver fibrosis is essential and the aim of our study was to compare and combine hemodynamic Doppler ultrasonography, liver stiffness by transient elastography, and non-invasive serum biomarkers with the degree of fibrosis confirmed by liver biopsy, and thereby to determine the value of combining non-invasive method in the prediction significant liver fibrosis. Material and methods: We included 102 patients with chronic liver disease of various etiology. Each patient was evaluated using Doppler ultrasonography measurements of the velocity and flow pattern a

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Papatheodoridi, Margarita, and Evangelos Cholongitas. "Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts." Current Pharmaceutical Design 24, no. 38 (2019): 4574–86. http://dx.doi.org/10.2174/1381612825666190117102111.

Повний текст джерела

Анотація:

Nonalcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. The majority of NAFLD patients do not progress to NASH and their morbidity risk is low. However, clinical and economic burden of the disease is considerable since the prevalence of the disease is estimated as high as 25% of the general population. Liver biopsy remains the current gold standard for diagnosis, despite limitations regarding sampling variability, invasive nature, and high cost. However, numerous non-invasive biomarkers, including mainly serum markers

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Haghgoo, Seyyed Mortaza, Heidar Sharafi, and Seyed Moayed Alavian. "Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review." Clinical Chemistry and Laboratory Medicine (CCLM) 57, no. 5 (2019): 577–610. http://dx.doi.org/10.1515/cclm-2018-0357.

Повний текст джерела

Анотація:

AbstractChronic liver disease (CLD) is a major health problem worldwide. Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC), chronic hepatitis B (CHB), and alcoholic liver disease (ALD) are the most common etiologies of CLD. Liver biopsy is the gold standard for assessment of liver fibrosis, however, it is an invasive method. This review attempts to evaluate the usefulness of serum adiponectin, serum leptin, serum ferritin, serum transforming growth factor-β1 (TGF-β1), and serum platelet derived growth factor-BB (PDGF-BB) as non-invasive markers in the diagnosis of liver fibr

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Stepanov, Yu M., V. I. Didenko, I. A. Klenina, O. M. Tatarchuk, and O. P. Petishko. "Improvement of liver fibrosis verification using new minimally invasive markers in patients with chronic diffuse liver diseases." Medicni perspektivi 27, no. 4 (2022): 100–114. http://dx.doi.org/10.26641/2307-0404.2022.4.271181.

Повний текст джерела

Анотація:

The aim of our research was to obtain new minimally invasive serum markers of fibrotic changes of liver in patients with chronic diffuse liver diseases of different etiology and compare them with traditional markers. 364 patients aged 30 to 66 years were examined: 221 women (60.7%) and 143 men (39.3%). Depending on the etiological factors, all patients were divided into 4 groups: group I consisted of 108 patients with non-alcoholic fatty liver disease (NAFLD), group II – 143 patients with chronic hepatitis associated with virus C (CHC), group III – 56 patients with alcoholic liver disease (ALD

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Xu, Xiaoming, Jiacheng Liu, Yixuan Zhu, Fajuan Rui, Chao Wu, and Jie Li. "Spleen stiffness measurement as a non-invasive assessment in patients with portal hypertension." eGastroenterology 2, no. 1 (2024): e100031. http://dx.doi.org/10.1136/egastro-2023-100031.

Повний текст джерела

Анотація:

For patients with advanced chronic liver disease who are in a compensated state, the development of portal hypertension (PHT) can lead to a heightened risk of hepatic decompensation and mortality. This underscores the importance of timely and appropriate treatment to manage the condition and prevent further complications. The current gold standard procedure for determining PHT is the hepatic venous pressure gradient, but its invasiveness limits its usage in clinical practice and larger trials of novel agents. The current clinical demand for accurate, validated and non-invasive methods to asses

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Кислюк, К. А., А. Н. Богданов, and С. Г. Щербак. "DIAGNOSIS OF CARDIAC FIBROSIS OF THE LIVER BY NON-INVASIVE TESTS IN PATIENTS WITH CHRONIC HEART FAILURE AND CHRONIC KIDNEY DISEASE." University therapeutic journal 5, no. 3 (2023): 110–19. http://dx.doi.org/10.56871/utj.2023.64.56.011.

Повний текст джерела

Анотація:

Застойные изменения в печени у больных хронической сердечной недостаточностью могут приводить к развитию кардиального фиброза печени, что ухудшает прогноз основного заболевания. В статье рассматриваются возможности диагностики кардиального фиброза с помощью ультразвуковой эластометрии печени, определения его серологических маркеров у больных с хронической сердечной недостаточностью различной степени и хронической болезнью почек. Установлено, что увеличение индексов BARD и MELD-XI свидетельствует о высоком риске кардиального фиброза и соотносится с результатами исследования жесткости печени при

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Maruvada, Sai Sindhuri, V. Sornavalli, I. Mariraj, and Poonam Balaganapathi. "Hand grip strength in patients with chronic liver disease and its reliability as a marker for malnutrition." Romanian Journal of Medical Practice 20, no. 1 (2025): 58–62. https://doi.org/10.37897/rjmp.2025.1.10.

Повний текст джерела

Анотація:

Background. Hand grip strength (HGS) is a simple clinical tool reflecting muscle function and overall health. In chronic liver disease (CLD), HGS is particularly relevant due to its association with malnutrition and sarcopenia. This study aimed to evaluate the relationship between HGS and nutritional status in CLD patients and its reliability as a marker of malnutrition and disease severity. Materials and methods. A cross-sectional study was conducted on 50 CLD patients using convenience sampling. Adult patients able to perform the HGS test were included. HGS was measured with a handheld dynam

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Agrawal, Swastik, Caroline L. Hoad, Susan T. Francis, Indra N. Guha, Philip Kaye, and Guruprasad P. Aithal. "Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease." Scandinavian Journal of Gastroenterology 52, no. 1 (2016): 107–15. http://dx.doi.org/10.1080/00365521.2016.1233578.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Kalinin, A. L., E. V. Tsitko, E. N. Snitsarenko, and T. V. Hvatik. "NONINVASIVE DIAGNOSTICS OF NON-ALCOHOLIC STEATOHEPATITIS." Health and Ecology Issues, no. 1 (March 28, 2011): 95–102. http://dx.doi.org/10.51523/2708-6011.2011-8-1-18.

Повний текст джерела

Анотація:

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of the increased contents of serum enzymes in chronic liver diseases. Its incidence rate is associated with the ongoing epidemics of obesity and diabetes of type 2. This multifaceted metabolic disorder is commonly encountered in clinical practice of various health care professionals ranging from primary care providers and gastroenterologists to cardiologists, radiologists and gynecologists. NAFLD comprises a spectrum of liver diseases from simple steatosis to full blown steatohepatitis that is characterized by steatosis

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Kumar, Shailesh, Vinay Kumar, Richa Giri, and S. K. Gautam. "Comparison of diagnostic accuracy of APRI and Transient Elastography for prediction of esophageal variceal bleed in liver cirrhosis." International Journal of Research in Medical Sciences 11, no. 5 (2023): 1721–26. http://dx.doi.org/10.18203/2320-6012.ijrms20231343.

Повний текст джерела

Анотація:

Background: Liver Cirrhosis is the end-stage for chronic liver disease. Repeated course of endoscopy is recommended, as this intervention is expensive and often poorly accepted by patients, there is a need for non-invasive methods to predicts the progression of portal hypertension as well as the presence and size of esophageal varices. This study was aimed to assess the APRI and Transient Elastography for predicting esophageal variceal bleed in cirrhotic patients. Objectives of the study were to study Diagnostic accuracy of APRI for Prediction of esophageal variceal bleed in liver cirrhosis, d

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Manka, Paul, Svenja Sydor, Julia M. Schänzer-Ocklenburg, et al. "A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver." Metabolites 12, no. 2 (2022): 130. http://dx.doi.org/10.3390/metabo12020130.

Повний текст джерела

Анотація:

Celiac disease (CeD) is a chronic autoimmune disorder characterized by an intolerance to storage proteins of many grains. CeD is frequently associated with liver damage and steatosis. Bile acid (BA) signaling has been identified as an important mediator in gut–liver interaction and the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Here, we aimed to analyze BA signaling and liver injury in CeD patients. Therefore, we analyzed data of 20 CeD patients on a gluten-free diet compared to 20 healthy controls (HC). We furthermore analyzed transaminase levels, markers of cell death, BA, an

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Munmun, Sayma Rahman, Mohammad Rukunuzzaman, Mohammad Wahiduzzaman Mazumder, et al. "Non-invasive diagnosis of liver fibrosis in children with chronic hepatitis B by transient elastography." Paediatrica Indonesiana 63, no. 4 (2023): 274–81. http://dx.doi.org/10.14238/pi63.4.2023.274-81.

Повний текст джерела

Анотація:

Background Chronic hepatitis B (CHB) is one of the most alarming global health problems. Children with CHB mostly remain asymptomatic but serious sequelae like cirrhosis and hepatocellular carcinoma may develop at any age. Liver biopsy, despite being the gold standard, is not preferable for the diagnosis of liver fibrosis because it is invasive and painful. Transient elastography, a noninvasive marker for fibrosis, could play an important role in this disease. Objective To observe the role of transient elastography in the assessment of the progression of liver damage in children with chr

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Veidal, Sanne Skovgård, Anne-Christine Bay-Jensen, Gervais Tougas, Morten Asser Karsdal, and Ben Vainer. "Serum Markers of Liver Fibrosis: Combining the BIPED Classification and the Neo-Epitope Approach in the Development of New Biomarkers." Disease Markers 28, no. 1 (2010): 15–28. http://dx.doi.org/10.1155/2010/548263.

Повний текст джерела

Анотація:

Background:Fibrosis is a central histological feature of chronic liver diseases and is characterized by the accumulation and reorganization of the extracellular matrix. The gold standard for assessment of fibrosis is histological evaluation of a percutaneous liver biopsy. Albeit a considerable effort have been invested in finding alternative non-invasive approaches, these have not been sufficiently succesfull to replace biopsy assessment.Aim:To identify the extracellular matrix proteins of interest, that as protein degradation fragments produced during extracellular matrix metabolism neo-epito

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Gonsalkorala, Enoka S., Mary D. Cannon, Tiong Yeng Lim, Leonie Penna, Catherine Willliamson, and Michael A. Heneghan. "Non-Invasive Markers (ALBI and APRI) Predict Pregnancy Outcomes in Women With Chronic Liver Disease." American Journal of Gastroenterology 114, no. 2 (2019): 267–75. http://dx.doi.org/10.1038/s41395-018-0181-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Lee, Han Hyo, Yeon Seok Seo, Soon Ho Um, et al. "Usefulness of Non-invasive Markers for Predicting Significant Fibrosis in Patients with Chronic Liver Disease." Journal of Korean Medical Science 25, no. 1 (2010): 67. http://dx.doi.org/10.3346/jkms.2010.25.1.67.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Ibrahim, Anam, Raza Rahim Hyder, Aamna Saaed, Sarah Nathaniel, Maryum Khalid, and Rabia Khan. "DIAGNOSTIC ACCITRACY OF DOPPLER WAVEFORM ABNORMALITIES OF HEPATIC VEINS IN PATIENTS OF CHRONIC LIVER DISEASE (HEPATITIS C VIRUS INFECTION) KEEPING HISTOPATHOLOGY AS A GOLD SIANDARD." Insights-Journal of Health and Rehabilitation 3, no. 2 (Health & Allied) (2025): 319–25. https://doi.org/10.71000/nh9k3p76.

Повний текст джерела

Анотація:

Background: Hepatic vein waveform abnormalities are a significant marker of liver fibrosis in patients with chronic liver disease, particularly those infected with Hepatitis C Virus (HCV). While liver biopsy remains the gold standard for diagnosing fibrosis, it is invasive and not suitable for routine screening. Doppler ultrasound offers a noninvasive alternative, yet its diagnostic accuracy in detecting hepatic venous abnormalities in HCV-related chronic liver disease remains inadequately defined. Objective: To determine the diagnostic accuracy of Doppler ultrasound in identifying hepatic vei

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Hashim, Ahmed, Stephen Bremner, Jane I. Grove, et al. "Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study." Liver International 42, no. 3 (2021): 628–39. http://dx.doi.org/10.1111/liv.15122.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Elkilany, Hesham H., Sameh M. Ghaly, Karim S. Abdullah, Wesam E. Wassfy, and Nouran M. Said. "Chronic hepatitis B infection biochemical, virological and tissue treatment response in correlation with platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR) in Egyptian patients infected with chronic hepatitis B virus." Egyptian Journal of Haematology 48, no. 4 (2023): 353–59. http://dx.doi.org/10.4103/ejh.ejh_42_23.

Повний текст джерела

Анотація:

Abstract Background Hepatitis B virus (HBV) is considered one of the most significant public health challenges due to its chronicity and complications that happen after several years of infection. The main event in HBV effect is its recognition as a foreign antigen which activates the immunity to target and destroy infected cells, hence HBV is not a cytotoxic virus. This destruction happens intermittently through the course of chronic infection leading to inflammation and necrosis of the liver tissue. The repetition of these periods of liver injury yields liver fibrosis and hepatocellular carc

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!